Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.18 USD
−90.21 M USD
0.00 USD
62.28 M
About Terns Pharmaceuticals, Inc.
Sector
Industry
CEO
Amy L. Burroughs
Website
Headquarters
Foster City
Founded
2017
FIGI
BBG00KK1SJ08
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The firm's pipeline includes clinical stage development programs, including a FXR agonist, a VAP-1 inhibitor, a THR-ß agonist, and a preclinical GLP-1 receptor agonist program. The company was founded by Randall L. Halcomb, Martijn Fenaux, and Weidong Zhong in 2017 and is headquartered in Foster City, CA.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of TERN is 6.80 USD — it has increased by 3.71% in the past 24 hours. Watch Terns Pharmaceuticals, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Terns Pharmaceuticals, Inc. stocks are traded under the ticker TERN.
TERN stock has risen by 6.73% compared to the previous week, the month change is a 7.22% rise, over the last year Terns Pharmaceuticals, Inc. has showed a 7.42% increase.
We've gathered analysts' opinions on Terns Pharmaceuticals, Inc. future price: according to them, TERN price has a max estimate of 34.00 USD and a min estimate of 7.50 USD. Watch TERN chart and read a more detailed Terns Pharmaceuticals, Inc. stock forecast: see what analysts think of Terns Pharmaceuticals, Inc. and suggest that you do with its stocks.
TERN reached its all-time high on Mar 19, 2021 with the price of 28.36 USD, and its all-time low was 1.45 USD and was reached on May 20, 2022. View more price dynamics on TERN chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
TERN stock is 4.79% volatile and has beta coefficient of 2.32. Track Terns Pharmaceuticals, Inc. stock price on the chart and check out the list of the most volatile stocks — is Terns Pharmaceuticals, Inc. there?
Today Terns Pharmaceuticals, Inc. has the market capitalization of 592.87 M, it has increased by 4.04% over the last week.
Yes, you can track Terns Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
Terns Pharmaceuticals, Inc. is going to release the next earnings report on Apr 1, 2025. Keep track of upcoming events with our Earnings Calendar.
TERN earnings for the last quarter are −0.28 USD per share, whereas the estimation was −0.32 USD resulting in a 12.62% surprise. The estimated earnings for the next quarter are −0.30 USD per share. See more details about Terns Pharmaceuticals, Inc. earnings.
Terns Pharmaceuticals, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
TERN net income for the last quarter is −21.95 M USD, while the quarter before that showed −22.74 M USD of net income which accounts for 3.48% change. Track more Terns Pharmaceuticals, Inc. financial stats to get the full picture.
No, TERN doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 18, 2024, the company has 66.00 employees. See our rating of the largest employees — is Terns Pharmaceuticals, Inc. on this list?
Like other stocks, TERN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Terns Pharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Terns Pharmaceuticals, Inc. technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Terns Pharmaceuticals, Inc. stock shows the sell signal. See more of Terns Pharmaceuticals, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.